Megan Sisk, DO
Pulmonary Disease · Great Falls, MTNPI 1306132279
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (30.7%), education and food and beverage — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Intuitive Surgical at 55.4% of the total. 2025 is the largest year on record at $11,905, more than ten times the $953 reported in 2019. Among pulmonary disease clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $78.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$11K
- Actelion Pharmaceuticals US, Inc.$5K
- AstraZeneca$590
- Boehringer Ingelheim$497
- GSK$477
- United Therapeutics Corporation$288
- plus $2K from 25 others
What the payments were for
- Consulting fees$3,12015%
- Travel & lodging$6,19731%
- Food & beverage$5,14126%
- Education$5,70228%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 31 | $11,171 |
| Actelion Pharmaceuticals US, Inc. | 49 | $5,365 |
| AstraZeneca | 34 | $590 |
| Boehringer Ingelheim | 22 | $497 |
| GSK | 23 | $477 |
| United Therapeutics Corporation | 16 | $288 |
| Merck | 13 | $255 |
| Insmed, Inc. | 7 | $211 |
| Pulmonx Corporation | 3 | $152 |
| Sanofi | 7 | $113 |
| Grifols USA, LLC | 5 | $112 |
| Mylan Specialty L.p. | 5 | $96 |
| Bayer | 5 | $88 |
| Sanofi-aventis U.S. LLC | 1 | $77 |
| Pfizer | 4 | $71 |
| Regeneron Healthcare Solutions, Inc. | 3 | $71 |
| E.r. Squibb & Sons, L.L.C. | 5 | $69 |
| Novartis | 3 | $67 |
| Mallinckrodt Hospital Products Inc. | 3 | $65 |
| Genentech USA, Inc. | 3 | $62 |
| Johnson & Johnson | 4 | $48 |
| Mallinckrodt Enterprises LLC | 2 | $40 |
| Davol Inc. | 1 | $35 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Harmony Biosciences LLC | 1 | $23 |
| Veran Medical Technologies, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| Bioventus LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Resmed Corp | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$10,258
- OPSUMIT$4,375
- UPTRAVI$4,375
How this compares
$20,160 in reported general payments places this provider in the 95th percentile of 43 pulmonary disease providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 11 | $132,650 |
| Orenitram ErTreprostinil Diolamine | 18 | $113,751 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 160 | $94,868 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $80,176 |
| Breo ElliptaFluticasone/Vilanterol | 139 | $59,476 |
| Dupixent SyringeDupilumab | 12 | $52,913 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $38,773 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 51 | $26,697 |
| Spiriva RespimatTiotropium Bromide | 26 | $16,185 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $9,471 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 131 | $3,990 |
| Ipratropium Bromide | 13 | $407 |
| Montelukast Sodium | 48 | $331 |
| Omeprazole | 26 | $182 |
| Pantoprazole Sodium | 12 | $115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $477 | $166,350286 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $5,365 | $132,65011 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $497 | $111,053186 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $590 | $48,24471 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 pulmonary disease providers in Montana.
Other pulmonary disease in Great Falls
- John MazurGreat Falls$18K
- Gabor VarjuGreat Falls$10K
- Merhala BalasubramaniamGreat Falls$1K
- Robert GrasseschiGreat Falls$458
- Sheela AhmedGreat Falls$158
- Sean DowGreat Falls$20
- Richard KearleyGreat Falls$16
- William KrauseGreat Falls$0
- Gregory LemenseBozeman$39K
- Bethany WeilerKalispell$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.